Fourth Quarter Financial Performance

BioNTech SE has disclosed a notable decline in its fourth-quarter revenue for fiscal 2024, with figures falling to €1.2 billion, marking a 24.4% decrease compared to the previous year. The company's net profit also saw a reduction, dropping to €259.5 million from €457.9 million in the same period last year. Additionally, the diluted earnings per share (EPS) were reported at €1.08, down from €1.88 a year ago.

Full Fiscal Year Overview

For the entirety of fiscal 2024, BioNTech's total revenues amounted to €2.7 billion, a decrease from the €3.8 billion recorded in 2023. The company experienced a diluted loss per share of €2.77, contrasting sharply with the earnings per share of €3.83 reported in the previous year.

Stay tuned for further updates on BioNTech's financial journey and strategic responses to these challenges.